ArticleCancer immunology, immunotherapy : CII2013

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.

Emmet McCormack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.